IL13 and eosinophilic esophagitis: Although anti–IL-13 antibodies have shown the ability to reduce esophageal eosinophilia, improve the molecular signature of esophageal inflammation, and reverse epithelial-mesenchymal transition, their impact on the clinical manifestation of EoE remains to be determined (56).